Table 3 HIV-1 subtypes and distribution of resistance-associated mutations among 16 patients with first-line ART failure attending three health centers in Djibouti city between October and December 2009
N° | SEX | CD4 | SUBTYPE | VL (cp/mL) | TREATMENT | NRTI | NNRTI | Major Mutation PI | Minor Mutation PI |
|---|---|---|---|---|---|---|---|---|---|
20 | F | 62 | C | 630 000 | AZT/3TC/EFV | None | None | None | None |
21 | M | 92 | C | 220 000 | AZT/3TC/EFV | None | None | None | None |
22 | F | 346 | C | 1 900 | AZT/3TC/EFV | None | None | None | None |
23 | M | 176 | C | 21 000 | AZT/3TC/EFV | None | None | None | None |
24 | F | 220 | C | 3270 | AZT/3TC/EFV | None | None | None | None |
25 | F | 243 | C | 7 500 | AZT/3TC/EFV | None | None | None | None |
26 | F | 103 | C | 413 000 | D4T/3TC/NVP | None | K101Q, Y181C | None | None |
27 | M | 52 | C | 26 000 | AZT/3TC/EFV | M184V | K103N | None | None |
28 | M | 249 | C | 213 000 | D4T/3TC/EFV | D67N, M184V, L210W, T215Y | Y188L, G190A | None | None |
29 | F | 230 | C | 1 080 000 | AZT/3TC/EFV | M41L, D67N, L74V, M184V, L210W, T215Y | K103N, G190A, H221Y, M230L | None | None |
30 | F | 140 | CRFO2_AG | 168 000 | D4T/3TC/EFV | None | None | None | None |
31 | F | 250 | CRF02_AG/C | 72 720 | AZT/3TC/NVP | K70KR, M184V, K219R | K103N | None | None |
32 | M | 92 | CRFO2_AG | 21 000 | AZT/3TC/EFV | T69N | V179E, Y188L | None | L10V |
33 | M | 88 | CRFO2_AG | 7 100 | AZT/3TC/EFV | M184V | K103N | None | L10V |
34 | F | 208 | B | 1 300 | D4T/3TC/NVP | A62V | None | None | None |
35 | M | 105 | B | 4 837 560 | AZT/3TC/EFV | A62V, M184V, T215F, K219Q | None | None | None |